Mutual Funds (UA-220086359-1)

Best Shares To Buy in Indian Market – Biocon

Biocon, the company which paved the way for Biotechnology in India to improve patient health.

This company is finding new ways of treatment to treat diabetes, cancer and autoimmune diseases.

Biocon’s Research & Development focuses on prevention, alleviation & treatment plus these medicines improve the lives of millions of patients in over 120 countries, giving more access to life-saving therapies and relief.

52 week high of this share is Rs410.70 and 52 week low is Rs297.55.
The market capitalization is Rs36,210 crores.
The Divided yield is 0.17/share.
This company is having a low PE ratio.
Best Shares To Buy in Indian Market – Biocon

Best Shares To Buy in Indian Market – Biocon

Income Statements:
Sales of the company in June, 2022 is Rs2139 Crores, compared to be Rs2408 Crores in March 2022. This is b’coz Pharma sector is facing recession after the COVID-19 crisis.
Total income in June,2022 is Rs2217 Crores, in June, 2022, compared to Rs2476 Crores in March, 2022.
Net profit has also come down to Rs210 Crores, in June, 2022, compared to Rs336 Crores in March,2022.
Company Reserve has been increased to Rs7832 Crores, in June, 2022 with comparison of Rs6931 Crores in March, 2022.
Total Assets has been increased to Rs20,394 crores, in June, 2022, compared with Rs18,522 Crore in March, 2022.

Best Shares To Buy in Indian Market – Biocon

Cash Flow:
Operating Activities has seen a rise of Rs1176 Crores in June,2022, compared with Rs1159 Crores in March, 2022.
Investing Activities has seen a major decrease in inputs from the company.
Financing Activities also, we can see a major decrease also.
Net Cash flow is –ve 243 Crores in June, 2022, compared with Rs106 Crores in March, 2022.
Earning Per Share is 5.44.
Face Value is Rs5.
Gross Profit Margin is 26.67%
Operating Margin is 16.72%.
Net Profit Margin has been decreased to 11.95% from 12.88%.
ROCE is 8.26% Current Ratio is 2.19,Quick Ratio is 1.59.
Debt To Equity is 0.58, Interest coverage ratio is 32.29.
3 year CAGR Sales is 21.82%, But 3 years CAGR Net Profit has come down to -1.16. P/E ratio is 61.69.

Promoters shareholding is 60.64%, Foreign Institutional Investors is 16.31%, Domestic Institutional Investors is 7.72%, and balance consists of public and others.

For Studying Investment Portfolio Strategy, Contact:-
Prof Subin : [Whatsapp] = 7000188030 [ India]
Email Id: greatsubin2018@gmail.com